There was unambigously good news about the company's single commercialized medication.Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (AMRN 7.07%), which received very encouraging news about its single commercialized drug that day. As a result, its shares were trading more than 6% higher in late-session trading on the stock market, eclipsing the basically flatlining S&P 500 index.A victory for VazkepaAmarin announced t ...

Core Viewpoint - Amarin Corporation has received a Decision to Grant from the European Patent Office for a new patent covering VAZKEPA, extending its exclusivity until 2039, which enhances the product's market potential in Europe [1][2]. Patent and Exclusivity Details - The new patent from the EPO will be granted on April 24, 2024, and will cover VAZKEPA in Europe until April 2039, based on the REDUCE-IT cardiovascular outcomes trial [3]. - Amarin successfully defended a separate patent related to VAZKEPA from third-party opposition, which is valid until June 2033 and pertains to reducing cardiovascular death risk [4]. - The existing exclusivity for VAZKEPA includes legacy patent protections from the ANCHOR study, extended via Supplemental Protection Certificates until June 2035, along with regulatory exclusivity until March 2031 [5].

Amarin Corporation Plc (AMRN) reported break-even quarterly earnings in fourth-quarter 2023 against the Zacks Consensus Estimate of a loss of 4 cents per share. The company recorded adjusted earnings of 2 cents in the year-ago quarter.Adjusted earnings exclude non-cash stock-based compensation, restructuring inventory and other restructuring expenses.Total revenues were $74.7 million, beating the Zacks Consensus Estimate of $72.5 million. However, revenues were down 17% from the year-ago quarter’s levels, o ...

Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Conference Call February 29, 2024 8:00 AM ET Company Participants Mark Marmur - Vice President, Global Corporate Communications Patrick Holt - President and Chief Executive Officer Tom Reilly - Executive Vice President, Chief Financial Officer and Head of Global HR & Finance Conference Call Participants Roanna Ruiz - Leerink Partners Operator Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2023 Financial Result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-21392 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------|-------------- ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin's senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A. The conference call with management will follow the release of the Company's fourth quar ...

It has been a rather lukewarm earnings season for the drug and biotech sector. Majority of large drug/biotech companies reported mixed results and issued fresh guidance for 2024, which was largely optimistic. Several smaller biotechs are scheduled to report earnings results this month.Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.Per the Earnings Trends report, as of Feb 14, 80.0% of the Me ...

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders: Dear Fellow Amarin Shareholders, 2023 was an important year for Amarin, marked by necessary transition and change. With a new board focused on shareholders, we undertook significant actions to strengthen the Company. We restructured t ...

sasirin pamai/iStock via Getty Images Amarin (NASDAQ:AMRN) isn't dead, after all. Sarissa seems to be doing what they promised to do - turning it around and giving it new life. I wasn't a believer before, but I could well become one soon. Things are looking that good. The Amarin story, very briefly, is this: fish oil has been used for ages as a health supplement. Fish oil contains omega-3 fatty acids, which has been assumed to be responsible for those health benefits. Omega-3 fatty acids are essential p ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amarin (AMRN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Amarin is one of 1077 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of ...